The estimated Net Worth of Olivier Brandicourt is at least 53.2 百万$ dollars as of 6 March 2013. Mr. Brandicourt owns over 113,364 units of Alnylam Pharmaceuticals Inc stock worth over 50,044,715$ and over the last 12 years he sold ALNY stock worth over 3,190,063$. In addition, he makes 0$ as Director at Alnylam Pharmaceuticals Inc.
Olivier has made over 2 trades of the Alnylam Pharmaceuticals Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he sold 113,364 units of ALNY stock worth 3,190,063$ on 6 March 2013.
The largest trade he's ever made was selling 113,364 units of Alnylam Pharmaceuticals Inc stock on 6 March 2013 worth over 3,190,063$. On average, Olivier trades about 4,225 units every 0 days since 2012. As of 6 March 2013 he still owns at least 191,076 units of Alnylam Pharmaceuticals Inc stock.
You can see the complete history of Mr. Brandicourt stock trades at the bottom of the page.
Olivier Brandicourt M.D. has been appointed as Director of the Company effective 3/2/2020. Dr. Brandicourt holds an Advanced Degree in Cellular and Immunological Pathophysiology from Paris Descartes University. He worked at the Institute of Infectious and Tropical Diseases at the Pitié-Salpêtrière Hospital in Paris with a focus on malaria research in West and Central Africa. Dr. Brandicourt formerly served as Chair of the Pharmaceutical Research and Manufacturers of America (PhRMA) Board, is an Honorary Fellow of the Royal College of Physicians in London, and is a Board member of the National Committee on United States-China Relations in New York. Since December 2019 Dr. Brandicourt has also served as a Senior Advisor at Blackstone.
Olivier Brandicourt is 64, he's been the Director of Alnylam Pharmaceuticals Inc since 2020. There are 6 older and 13 younger executives at Alnylam Pharmaceuticals Inc. The oldest executive at Alnylam Pharmaceuticals Inc is Phillip Sharp, 75, who is the Independent Director.
Olivier's mailing address filed with the SEC is C/O MOURANT GOVERNANCE SERVICES (CAYMAN), 94 SOLARIS AVE, CAMANA BAY, GRAND CAYMAN, E9, KY1-1108.
Over the last 20 years, insiders at Alnylam Pharmaceuticals Inc have traded over 140,068,015$ worth of Alnylam Pharmaceuticals Inc stock and bought 4,419,116 units worth 1,983,132,563$ . The most active insiders traders include Sanofi、Christoph H Westphal、Kevin P Starr. On average, Alnylam Pharmaceuticals Inc executives and independent directors trade stock every 23 days with the average trade being worth of 11,181,724$. The most recent stock trade was executed by Yvonne Greenstreet on 20 August 2024, trading 15,000 units of ALNY stock currently worth 1,275,000$.
alnylam is developing an entirely new class of innovative medicines based on a breakthrough discovery in biology known as rna interference, or rnai. with rnai technology, we have the opportunity to treat disease and impact the lives of patients in a fundamentally new way by silencing disease-causing genes upstream of today's medicines.
Alnylam Pharmaceuticals Inc executives and other stock owners filed with the SEC include: